免疫學領域的合作與授權協議（2016-2025）

本報告以前所未有的方式，全面深入地展現了全球領先的生物製藥公司簽署的免疫學相關合作與許可協議。

本報告詳細介紹了2016年至2025年間909項免疫學相關交易。

本報告提供了各方已公佈交易的付款條款。這些數據有助於深入了解付款條款和其他交易條款。

了解潛在合作夥伴協商的交易條款的彈性，有助於深入了解談判過程，從而預估談判的預期成果。雖然許多中小企業會尋求詳細的付款條款，但魔鬼藏在細節裡，尤其是在付款方式和權利轉讓方面。

本報告全面列出了自 2016 年以來在 "當前協議交易與聯盟" 資料庫中記錄的所有合作與許可協議，包括財務條款（如有）以及公司及其合作夥伴向美國證券交易委員會 (SEC) 提交的實際許可協議的線上副本連結。

本報告第一章探討了免疫學領域的交易和商業活動。第一章為報告的引言，第二章分析了免疫學領域的交易趨勢。

第三章介紹了免疫學領域已完成交易的財務條款和發展階段。交易按總價值、首付款、里程碑付款和特許權使用費率進行分類。

第四章回顧了在免疫學交易中最活躍的 25 家生物製藥公司。對於已向 SEC 公開披露的協議，可透過 "當前協議交易與聯盟" 資料庫線上存取。

第五章對2016年以來已完成和已宣布的免疫學交易進行了全面深入的回顧，這些交易均有相關文件可供查閱。每項交易標題都提供了一個指向在線交易文件的鏈接，方便讀者隨時查閱。

第六章提供了一個按目標公司分類的免疫學交易綜合目錄。

本書也包含大量圖表，展示了自2016年以來免疫學交易的趨勢和活動。

此外，此綜合交易目錄按公司名稱（A-Z）和技術類型進行分類。每項交易標題都提供了一個指向在線交易記錄的鏈接，並在可用的情況下提供協議文件，方便讀者隨時查閱。

主要優勢

"免疫學領域的合作與授權協議" 提供讀者以下主要優勢：

• 了解自 2016 年以來的交易趨勢
• 瀏覽免疫學領域的合作與授權交易
• 基準分析 - 確定交易的市場價值
• 財務條款 - 預付款、里程碑付款、特許權使用費
• 按公司 A-Z、治療領域和技術類型分類的交易目錄
• 主要交易金額
• 最活躍的交易撮合者
• 確定每筆交易的資產和交易條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款是否適合您的合作夥伴
• 節省數百小時的研究時間

範圍

• 免疫學領域的合作與授權協議 "授權協議報告" 旨在幫助全球領先的生物製藥公司深入了解免疫學領域的趨勢和交易結構。

免疫學合作與授權協議包括：

• 生物製藥產業免疫學相關交易趨勢
• 合作與授權協議架構概述
• 涵蓋製藥和生物技術的免疫學交易記錄目錄
• 主要免疫學交易
• 最活躍的免疫學許可公司

以下列出了可用的免疫學合作與授權交易。

• 公司 A-Z
• 主要交易金額
• 治療領域
• 技術類型
• 每個交易標題都透過網路連結指向實際的線上交易記錄，方便您輕鬆存取每份協議文件。
• 免疫學領域的合作與授權協議提供對交易記錄（包括協議文件）的全面存取。

對這些協議的分析有助於進行盡職調查，包括：

• 具體授予或選擇哪些權利？
• 根據合同，合作夥伴實際獲得哪些權益？
• 授予了哪些排他性權利？
• 合約的付款結構是什麼？
• 如何對銷售和付款進行審計？
• 合約期限是多久？
• 如何定義合約的關鍵條款？
• 如何處理並擁有知識產權？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 在什麼情況下可以終止合約？
• 如果所有權發生變更，會發生什麼事？
• 已達成哪些轉許可或分包條款？
• 公司堅持哪些標準條款？
• 哪些標準條款似乎因合作夥伴和交易類型而異？
• 公司主張其在契約法方面享有哪一個管轄權？

目錄

摘要整理

第一章：引言

第二章：免疫學交易趨勢

• 引言
• 長期免疫學合作
• 按交易類型劃分的免疫學合作
• 按行業劃分的免疫學合作
• 依研發階段劃分的免疫學合作
• 按技術類型劃分的免疫學合作
• 按治療適應症劃分的免疫學合作

第三章：免疫學合作的財務條款

• 引言
• 揭露免疫學合作的財務條款
• 關鍵價值策略免疫學合作
• 免疫學交易中的預付款
• 免疫學交易中的里程碑付款
• 免疫學特許權使用費率

第四章：重要的免疫學交易與交易撮合者

• 引言
• 最活躍的免疫學合作者
• 最活躍的免疫學交易撮合者名單
• 以價值為排名的頂級免疫學交易

第五章：免疫學合約文件目錄

• 引言
• 可提供合約的免疫學合作協議

第六章：依治療標靶分類的免疫學交易

• 引言
• 以免疫療法標靶分類的交易
• 交易目錄
• 交易目錄 -免疫學領域交易（按公司、亞利桑那州、2016-2025 年）
• 交易目錄 - 免疫學領域交易（依技術類型、2016-2025 年）
• 交易類型定義
• 關於研究公司
• 當前合作關係
• 當前協議
• 近期當前合作關係報告標題

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 909 immunology deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of immunology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse immunology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Immunology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of immunology trends and structure of deals entered into by leading biopharma companies worldwide.

Immunology Collaboration and Licensing Deals includes:

• Trends in immunology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of immunology deal records covering pharmaceutical and biotechnology
• The leading immunology deals by value
• Most active immunology licensing dealmakers

In Immunology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Immunology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in immunology dealmaking

• 2.1. Introduction
• 2.2. Immunology partnering over the years
• 2.3. Immunology partnering by deal type
• 2.4. Immunology partnering by industry sector
• 2.5. Immunology partnering by stage of development
• 2.6. Immunology partnering by technology type
• 2.7. Immunology partnering by therapeutic indication

Chapter 3 - Financial deal terms for immunology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for immunology partnering
• 3.3. Immunology partnering headline values
• 3.4. Immunology deal upfront payments
• 3.5. Immunology deal milestone payments
• 3.6. Immunology royalty rates

Chapter 4 - Leading immunology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in immunology partnering
• 4.3. List of most active dealmakers in immunology
• 4.4. Top immunology deals by value

Chapter 5 - Immunology contract document directory

• 5.1. Introduction
• 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by immunology therapeutic target
• Deal directory
• Deal directory - Immunology deals by company A-Z 2016 to 2025
• Deal directory - Immunology deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Immunology partnering since 2016
• Figure 2: Immunology partnering by deal type since 2016
• Figure 3: Immunology partnering by industry sector since 2016
• Figure 4: Immunology partnering by stage of development since 2016
• Figure 5: Immunology partnering by technology type since 2016
• Figure 6: Immunology partnering by indication since 2016
• Figure 7: Immunology deals with a headline value
• Figure 8: Immunology deals with upfront payment values
• Figure 9: Immunology deals with milestone payment
• Figure 10: Immunology deals with royalty rates
• Figure 11: Active immunology dealmaking activity since 2016
• Figure 12: Top immunology deals by value since 2016